Neurological Institute Outcomes
Surgical Quality Improvement
Brain Tumor Surgery Outcomes
Brain Tumor Surgery ACS NSQIP Outcomes
January 1, 2021 – December 31, 2021
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall brain tumor surgery ACS NSQIP performance benchmarked against 207 participating sites.
| Brain Tumor (207 Sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Mortality | 272 | 2.21% | 2.77% |
| 30 Day Morbidity | 272 | 10.66% | 10.02% |
| Cardiac | 272 | 0.37% | 0.85% |
| Unplanned Intubation | 272 | 1.10% | 2.23% |
| Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 272 | 6.25% | 3.19% |
| Urinary Tract Infection (UTI) | 272 | 0.37% | 1.72% |
| Surgical Site Infection (SSI) | 272 | 2.57% | 1.87% |
| Return to Operating Room (ROR) | 272 | 4.41% | 4.55% |
American College of Surgeons National Surgical Quality Improvement Program, 2022.
ACS NSQIP® Semiannual Report July 12, 2022, Chicago: American College of Surgeons.
